Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) has been assigned an average recommendation of “Buy” from the eight ratings firms that are currently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $9.00.
Several analysts have recently issued reports on PYXS shares. Jefferies Financial Group reissued a “buy” rating and set a $10.00 price objective on shares of Pyxis Oncology in a research note on Tuesday, May 7th. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research report on Thursday, May 16th. Finally, Stifel Nicolaus initiated coverage on Pyxis Oncology in a research report on Thursday, August 8th. They set a “buy” rating and a $10.00 target price on the stock.
Check Out Our Latest Stock Analysis on Pyxis Oncology
Pyxis Oncology Price Performance
Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last posted its quarterly earnings results on Saturday, May 11th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.19. The business had revenue of $16.15 million during the quarter, compared to analysts’ expectations of $4.25 million. On average, analysts anticipate that Pyxis Oncology will post -1.09 EPS for the current year.
Institutional Trading of Pyxis Oncology
A number of institutional investors and hedge funds have recently modified their holdings of PYXS. Fullcircle Wealth LLC acquired a new position in shares of Pyxis Oncology during the second quarter valued at $40,000. SG Americas Securities LLC acquired a new position in Pyxis Oncology during the 1st quarter valued at about $59,000. Cetera Advisors LLC bought a new position in Pyxis Oncology in the 1st quarter worth about $100,000. Schulhoff & Co. Inc. increased its stake in shares of Pyxis Oncology by 90.9% in the second quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock valued at $139,000 after purchasing an additional 20,000 shares during the period. Finally, American Century Companies Inc. raised its holdings in shares of Pyxis Oncology by 56.0% during the second quarter. American Century Companies Inc. now owns 58,252 shares of the company’s stock valued at $193,000 after buying an additional 20,901 shares during the last quarter. 39.09% of the stock is owned by institutional investors and hedge funds.
About Pyxis Oncology
Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Recommended Stories
- Five stocks we like better than Pyxis Oncology
- Options Trading – Understanding Strike Price
- Brinker International’s Price Dip is an Appetizing Entry Point
- What to Know About Investing in Penny Stocks
- 3 Stocks That Could Beat the September Blues
- Consumer Staples Stocks, Explained
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.